LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivaNova PLC on September 21, 2023, reporting events occurring on September 18, 2023. The filing addresses a significant executive departure within the Company's leadership structure.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a specific executive compensation arrangement.
- Retirement Payment: Marco Dolci will receive an aggregate retirement payment of €860,000.
Material Changes
The primary material change reported is the announced retirement of Marco Dolci, President of the Cardiopulmonary Business Unit.
- Departure Date: Mr. Dolci will formally retire on December 31, 2023.
- Transition Plan: He will continue in his current role until the retirement date to support the transition of his responsibilities.
- Employment History: Mr. Dolci joined the Company in March 2017 and has served as President, Cardiopulmonary, since February 2022.
Management Commentary and Agreements
The Company entered into a Retirement Settlement Agreement dated September 18, 2023. Key terms include:
- Mr. Dolci will receive regular remuneration and benefits until the retirement date.
- Outstanding and unvested equity awards will continue to vest according to their respective award agreements.
- The agreement includes customary provisions under Italian law, such as mutual releases and waivers of claims.
The filing does not contain forward-looking guidance, outlook, or specific risk factors beyond the standard legal provisions of the settlement agreement.
Investor Verification Checklist
- Verify the timeline for appointing a successor to the President of the Cardiopulmonary Business Unit.
- Confirm the impact of the €860,000 retirement payment on the Company's upcoming quarterly or annual financial statements.
- Review the vesting schedule of Mr. Dolci's equity awards to understand potential dilution or expense recognition.
- Monitor subsequent filings for the official appointment of the new Cardiopulmonary Business Unit President.